



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of **Goddard et al.**) Examiner: Gyan Chandra
Serial No. 10/735,014) Group Art Unit: 1646
Filed: December 12, 2003) Attorney's Docket No. 10466/486
Title: **SECRETED AND**)
TRANSMEMBRANE)
POLYPEPTIDES AND NUCLEIC)
ACIDS ENCODING THE SAME)

DECLARATION OF AUDREY GODDARD, Ph.D., PAUL J. GODOWSKI, Ph.D.,
J. CHRISTOPHER GRIMALDI, AUSTIN L. GURNEY, Ph.D., DANIEL TUMAS, Ph.D.
AND WILLIAM I. WOOD, Ph.D. UNDER 37 CFR § 1.131

MAIL STOP AMENDMENT

The Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

We, Audrey Goddard, Ph.D., Paul J. Godowski, Ph.D., J. Christopher Grimaldi, Austin Gurney, Ph.D., Daniel Tumas, Ph.D. and William I. Wood, Ph.D. declare and say as follows:

1. We are the inventors of the above-identified application.
2. At the time the present invention was made, one of the inventors, Daniel Tumas, Ph.D., was responsible for overseeing the testing of novel polypeptides, including the polypeptide PRO361, in an assay of inhibitory activity in the mixed lymphocyte relation (MLR) (Assay #67, Example 34). This assay is used to find agents that are active as inhibitors of the proliferation of stimulated T-lymphocytes. Compounds which inhibit proliferation of lymphocytes are useful therapeutically where suppression of an immune response is beneficial.
3. The basic protocol for this assay is described in Current Protocols in Immunology, unit 3.12, edited by J E Coligan, A M Kruisbeek, D H Marglies, E M Shevach, W Strober, National Institutes of Health, Published by John Wiley & Sons, Inc.

More specifically, in one assay variant, peripheral blood mononuclear cells (PBMC) are isolated from mammalian individuals, for example a human volunteer, by leukopheresis (one donor will supply stimulator PBMCs, the other donor will supply responder PBMCs). If desired, the cells are frozen in fetal bovine serum and DMSO after isolation. Frozen cells may be thawed overnight in assay media (37°C, 5% CO₂) and then washed and resuspended to 3x10⁶ cells/ml of assay media (RPMI; 10% fetal bovine serum, 1% penicillin/streptomycin, 1% glutamine, 1% HEPES, 1% non-essential amino acids, 1% pyruvate). The stimulator PBMCs are prepared by irradiating the cells (about 3000 Rads).

The assay is prepared by plating in triplicate wells a mixture of:

100:1 of test sample diluted to 1% or to 0.1%,

50:1 of irradiated stimulator cells, and

50:1 of responder PBMC cells.

100 microliters of cell culture media or 100 microliter of CD4-IgG is used as the control. The wells are then incubated at 37°C, 5% CO₂ for 4 days. On day 5, each well is pulsed with tritiated thymidine (1.0 mCi/well; Amersham). After 6 hours the cells are washed 3 times and then the uptake of the label is evaluated.

In another variant of this assay, PBMCs are isolated from the spleens of Balb/c mice and C57B6 mice. The cells are teased from freshly harvested spleens in assay media (RPMI; 10% fetal bovine serum, 1% penicillin/streptomycin, 1% glutamine, 1% HEPES, 1% non-essential amino acids, 1% pyruvate) and the PBMCs are isolated by overlaying these cells over Lympholyte M (Organon Teknika), centrifuging at 2000 rpm for 20 minutes, collecting and washing the mononuclear cell layer in assay media and resuspending the cells to 1x10⁷ cells/ml of assay media. The assay is then conducted as described above.

Any decrease below control is considered to be a positive result for an inhibitory compound, with decreases of less than or equal to 80% being preferred. However, any value less than control indicates an inhibitory effect for the test protein. The results are indicative of the utility of the PRO polypeptides in therapeutic applications where suppression of an immune response is beneficial.

in therapeutic applications where suppression of an immune response is beneficial.

4. Copies of pages from an internal database showing the positive results for the PRO361 polypeptide (SEQ ID NO: 83), identified by Pin number PIN996-1, in Assay #67 are attached to this declaration (with dates redacted) as Exhibit A. These experiments were performed and the results were obtained in the United States prior to August, 1999.

5. Exhibit A clearly shows that the polypeptide designated PRO361 was tested, and its ability to inhibit the mixed leukocyte reaction was determined prior to August, 1999.

6. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

A. Goddard
Audrey Goddard, Ph.D.

1/12/08
Date

Paul J. Godowski, Ph.D.

Date

J. Christopher Grimaldi

Date

Austin L. Gurney, Ph.D.

Date

Daniel Tumas, Ph.D.

Date

William I. Wood, Ph.D.

Date



in therapeutic applications where suppression of an immune response is beneficial.

4. Copies of pages from an internal database showing the positive results for the PRO361 polypeptide (SEQ ID NO: 83), identified by Pin number PIN996-1, in Assay #67 are attached to this declaration (with dates redacted) as Exhibit A. These experiments were performed and the results were obtained in the United States prior to August, 1999.

5. Exhibit A clearly shows that the polypeptide designated PRO361 was tested, and its ability to inhibit the mixed leukocyte reaction was determined prior to August, 1999.


6. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Audrey Goddard, Ph.D.



Paul J. Godowski, Ph.D.

Date



Date

J. Christopher Grimaldi

Date

Austin L. Gurney, Ph.D.

Date

Daniel Tumas, Ph.D.

Date

William I. Wood, Ph.D.

Date



in therapeutic applications where suppression of an immune response is beneficial.

4. Copies of pages from an internal database showing the positive results for the PRO361 polypeptide (SEQ ID NO: 83), identified by Pin number PIN996-1, in Assay #67 are attached to this declaration (with dates redacted) as Exhibit A. These experiments were performed and the results were obtained in the United States prior to August, 1999.

5. Exhibit A clearly shows that the polypeptide designated PRO361 was tested, and its ability to inhibit the mixed leukocyte reaction was determined prior to August, 1999.

6. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Audrey Goddard, Ph.D.

Date

Paul J. Godowski, Ph.D.


Date

J. Christopher Grimaldi

Date

Austin L. Gurney, Ph.D.

Date




Daniel Tumas, Ph.D.

February 14, 2008
Date

William I. Wood, Ph.D.

Date



in therapeutic applications where suppression of an immune response is beneficial.

4. Copies of pages from an internal database showing the positive results for the PRO361 polypeptide (SEQ ID NO: 83), identified by Pin number PIN996-1, in Assay #67 are attached to this declaration (with dates redacted) as Exhibit A. These experiments were performed and the results were obtained in the United States prior to August, 1999.

5. Exhibit A clearly shows that the polypeptide designated PRO361 was tested, and its ability to inhibit the mixed leukocyte reaction was determined prior to August, 1999.

6. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Audrey Goddard, Ph.D.

Date

Paul J. Godowski, Ph.D.

Date

J. Christopher Grimaldi

Date

Austin L. Corney, Ph.D.

Date 1/8/08

Daniel Tumas, Ph.D.

Date

William I. Wood, Ph.D.

Date



in therapeutic applications where suppression of an immune response is beneficial.

4. Copies of pages from an internal database showing the positive results for the PRO361 polypeptide (SEQ ID NO: 83), identified by Pin number PIN996-1, in Assay #67 are attached to this declaration (with dates redacted) as Exhibit A. These experiments were performed and the results were obtained in the United States prior to August, 1999.

5. Exhibit A clearly shows that the polypeptide designated PRO361 was tested, and its ability to inhibit the mixed leukocyte reaction was determined prior to August, 1999.

6. We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information or belief are believed to be true, and further that these statements were made with the knowledge that willful statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful statements may jeopardize the validity of the application or any patent issued thereon.

Audrey Goddard, Ph.D.

Date

Paul J. Godowski, Ph.D.

Date

J. Christopher Grimaldi


Date

Austin L. Gurney, Ph.D.

Date

Daniel Tumas, Ph.D.

Date



William I. Wood, Ph.D.

Date

12/14/17

EXHIBIT A

GenesGenes Enter search terms



SEARCH REQUEST SYSTEMS ANALYSIS TOOLS RESOURCES Historical SPDI Record

Quick search: DNA Enter ID number

Assay Viewer
SPDI A44895

- AST517 Rod Photoreceptor Cell cAMP Synergy (2 Da)
- AST518 Rat DRG Neuronal Survival Inhibition Assay
- AST519 Ventralization of Xenopus Embryo by DNA
- AST560 Benzodiazepine Scavenging of Xenopus Embryo by DNA
- AST561 Ventralization of Xenopus Embryo by DNA
- AST562 Ventralization of Xenopus Embryo by DNA
- AST563 Neuroprotection of stem cell proliferation
- AST564 Proliferation/PNH Inhibition
- AST565 HUVEC Survival in Absence of Serum
- AST566 Inhibition of Apoptosis Differentiation
- AST567 MLK - Inhibition

Look for Search

Find Lots
All PNH
All DNA

Show Lots for:
LOT 176
Number: 176
Include UNQ Related Lots

☐ All Positives ☐ Verified Positives ☐ Pending

Date Complete From

ASSAY RESULT LIST
AST AST Name
AST517 MLK-Inh
AST518 MLK-Inh
AST519 MLK-Inh
AST520 MLK-Inh

Rows 1 - 4 of 4
LOT LOT Name
LOT176 PNH996-1
LOT176 PNH996-1
LOT176 PNH996-1
LOT176 PNH996-1

Page 1 of 1
Cons Conc Unit Mean Ctl
1.50 nM 63.2
1.50 nM 77.3
15.00 nM 64.7
15.00 nM 99.4

Select Page Page No. 1
UNQ UNQ Name
UNQ316 Human MAHSC1 IgG
UNQ316 Human MAHSC1 IgG
UNQ316 Human MAHSC1 IgG
UNQ316 Human MAHSC1 IgG

Date Date Data Complete Comment

Info | Feedback | Silences
GenesGenes is maintained by Bioinformatics